DARE DARE BIOSCIENCE INC Capital Structure Changes 8-K Filing 2024 - Compliance regained with Nasdaq listing requirements Dare Bioscience regains compliance with Nasdaq listing requirements and continues progress on Phase 3 studies for Sildenafil Cream.Get access to all SEC 8-K filings of the DARE BIOSCIENCE INC